Advicenne

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.